Press Releases

The rule and its compliance deadlines are no longer in effect, benefiting patient care, innovation, and the greater laboratory community, ARUP leaders said.

Pramana, Inc., and ARUP are collaborating to improve the assessment of bone marrow biopsies and address other key diagnostic challenges in hematopathology.

ARUP will expand its AI-augmented screening tool for the detection of human gastrointestinal parasites to become first and only lab to apply AI to the entire ova and parasite testing process.

The partnership combines Tasso’s clinical grade blood collection solutions and ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research.

ARUP has launched a new assay for the detection and subtyping of influenza A (H5) virus, which will expand the national capacity to detect the current outbreak of highly pathogenic avian influenza A (H5N1).

ARUP Laboratories is partnering with Augurex Life Sciences Corp. to include the 14-3-3η test in the ARUP test menu to enhance the early detection of rheumatoid arthritis.

ARUP has been awarded a CDC contract for avian influenza A (H5N1) test development, which recognizes our expertise and experience with assay development and our desire to serve public health needs.

The new Sherrie Perkins Research and Innovation Collaboration Grant, designed to foster collaboration in healthcare, will fund cutting-edge research in lab medicine that could impact patient care.

ARUP’s declaration amplifies the lawsuit’s claims that the FDA does not have legal authority over laboratory testing services and that regulating these services is unreasonable.

ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs.